

Technology Catalysts International (TCI) was founded in 1979 to provide consulting services that satisfy the licensing and business research needs of the drug delivery, pharmaceutical, and chemical industries. We specialize in technology licensing, technology assessment, and technology portfolio management. The firm is headquartered in Falls Church, Virginia, a suburb of Washington D.C. Our global network includes offices in Japan, Korea, India, Argentina, the United Kingdom, Germany, China, and Czech Republic.

Our research staff is composed of professionals with backgrounds in a variety of technical disciplines with additional expertise in international marketing, licensing, finance, and business development. The breadth of our experience assures clients of high quality, actionable information, and complete coverage on topics of interest.

TCI's core consulting services are based on continuous monitoring of global technology development. We provide consulting and technology transfer services to leading product developers and manufacturers in North and South America, Europe, and Asia. Our client base consists of small, medium, and large corporations.

For more information on our services and capabilities, please visit our website at:

www.technology-catalysts.com

Worldwide contacts for additional information

World Headquarters

Ajay Rastogi
Vice President
Technology Catalysts International Corporation
605 Park Avenue
Falls Church, VA 22046 USA
Telephone: (703) 531-0257
Facsimile: (703) 237-0042
E-mail: arastogi@technology-catalysts.com
Internet: www.technology-catalysts.com

Europe

Graham L. Crawford, MSc
Managing Director
Technology Catalysts International UK
Blacksmiths
Clifton Road
Newton Blossomville
Bedford MK43 8AS UK
Telephone: +44 1234 881583
Facsimile: +44 1234 881027
E-mail: gercrawford@technology-catalysts.com

Gerhard Wallenwein, Ph.D.
Managing Director
Laves Chemie Consulting
Koenigsteiner Strasse 80
D-65812 Bad Soden, Germany
Telephone: +49 6196 62057
Facsimile: +49 6196 27837
E-mail: laveschemie@t-online.de
Internet: www.laveschemie.de

Jana Kuhnlova
Managing Director
Inventia s.r.o.
Na Belidle 3
150 00 Praha 5 - Smíchov, Czech Republic
Telephone: +420 2 22247484
Facsimile: +420 2 24218645
E-mail: kuhnlova@inventia.cz
Internet: www.inventia.cz

Milos Hrabá
Manager NBD
Inventia s.r.o.
Na Belidle 3
150 00 Praha 5 - Smíchov, Czech Republic
Telephone: +420 2 22247484
Facsimile: +420 2 24218645
E-mail: hraba@inventia.cz

South America

Carlos A. Massone M.D.
President
Qualia S.A.
Jeronimo Salguero 2533, Piso 12 "A"
1425, Buenos Aires, Argentina
Telephone: +54 11 4807 3433
Facsimile: +54 11 4807 2933
E-mail: carlos.massone@qualia.com.ar
Internet: www.qualia.com.ar

Asia

Sansei Oka
Japanese Business Representative
Technology Catalysts International
4-18-11-101, Takada-Higashi
Kohoku-Ku, Yokohama 223-0065, Japan
Telephone: +81 45 543 5578
E-mail: soka@technology-catalysts.com

Mitsuhsu Tamura
Senior Research Associate
Sumika Technical Information Service Inc.
15 Fl., Tokyo Sumitomo Twin Bldg. (East)
27-1, Shinkawa 4-chome
Chuo-ku, Tokyo 104-0033, Japan
Telephone: +81 3 5543 5875
Facsimile: +81 3 5543 5945
E-mail: mitsuhsu-tamura@ya.sumitomo-chem.co.jp
Internet: www.stis.co.jp

Don Ki Kim
President & CEO, Pharmacist
Global Damon Pharma
Seoul
Korea
Telephone: +82 2 3673-2367
Facsimile: +82 2 3673-2369
E-mail: dlkim@gdp.co.kr

Mr. Jaison Abraham
General Manager
TCI India
Level 4, Dynasty, 'A' Wing
Andheri-Kurla Road
Andheri East
Mumbai 400 069, India
Telephone: +91-22-4030 9499
Facsimile: +91-22-4030 9199
Mobile: +91-98-1932 8598
E-mail: jabraham@technology-catalysts.com


Mr. R.K. Gupta
Managing Director
Industrial Development Services Pvt. Ltd.
M-1 Kanchenjunga
18 Barakhamba Road
New Delhi 110 001, India
Telephone: +91-11- 2 351 2287; 2 351 4714
Facsimile: +91-11-23738227
E-mail: ids@del2.vsnl.net.in
Internet: www.ids-india.org

Visit TCI's website at:

www.technology-catalysts.com

© 2010 Technology Catalysts International

Cancer Vaccines Report



Cancer vaccines have the potential to dramatically alter the treatment of cancer. While there are many treatment options for cancer, currently there is no cure. However, there are products on the market for use as prophylactics for cancer and the first therapeutic cancer vaccine was recently approved. For this and many other reasons, companies have begun exploring alternative methods for preventing, treating, and hopefully eventually curing cancer.

Cancer vaccines are still a relatively new approach to cancer and many technical hurdles need to be overcome. According to the FDA the first preventative cancer vaccines on the market were designed to prevent hepatitis B, the leading cause of primary cancer. The more recent prophylactic cancer vaccines that have gained worldwide attention are Gardasil® by Merck and Cervarix® by GSK. These vaccines are indicated for certain types of cancer-causing human papillomavirus (HPV). In April 2010, the FDA approved the first therapeutic vaccine for cancer. Provenge®, developed by Dendreon, is indicated for the treatment of advanced prostate cancer.

Although one of these products, Gardasil, has already reached blockbuster sales, there are many challenges to overcome before the full therapeutic potential is realized. The biggest hurdles include seeking the right antigen, selecting the right adjuvant, and developing a technology to effectively deliver the product to the right location. To address these obstacles, there are a number of companies that are developing novel approaches to successfully create effective cancer vaccines.

Technology Catalysts International (TCI) has developed a report that analyzes the current technology and market potential for cancer vaccines. This report features a pipeline overview, a market analysis, and a summary of recent deals associated with cancer vaccines. In addition, the report provides detailed descriptions of novel technologies designed for the development of cancer vaccines. The information is confirmed via company interviews and includes full contact information for easy follow-up and business development opportunities.

This report provides insight and an overview of the current development of cancer vaccines and the types of delivery methodologies used in their development. TCI covers the market for key cancer types and associated launched products based on historic product sales and trends in the overall vaccine market. There are detailed descriptions of more than 35 companies in this report that have active developments into various approaches to cancer vaccines, both in early or late stage.

Key Information Presented

Product and Technology Introductions

- Overview and background on cancer vaccine development
- Companies and pipelines categorized by type of vaccine
 - Therapeutic
 - Prophylactic
- Companies and pipelines categorized by delivery method
 - DNA-based
 - mRNA/RNAi/siRNA
 - Bacteria and virus delivery
- Academic research
- Major cancer vaccine industry deals and collaborations

Market Landscape Analysis of Cancer Vaccine Technologies

- Overall oncology market compared to other therapeutic classes
- Sales of leading cancer vaccines in 2009
- Estimates of US national expenditures for cancer care, 2006
- Market overview for key types of cancer
- Market for top selling vaccines and cancer vaccines from 2007-2012

Technology Licensing Opportunities

- Detailed profiles of cancer vaccine technologies
- Technologies from US, Asia, and EU
- Updated contact information to initiate licensing agreements

ORDER FORM

Per Copy (Paper Copy PDF Copy)\$3,950.

Extra paper copies x _____ \$ 500. ea.

Note: All prices are U.S. dollars

Total Amount Due: _____

Shipping/Purchase Information:

Name _____

Title _____

Company _____

Address _____

Telephone _____

Facsimile _____

Email _____

Signature _____

Date _____

Credit Card (MC Visa Amex)

Card Number _____

Expiration Date _____ Security code (3 or 4 digits) _____

Check enclosed, made payable to Technology Catalysts International

Send invoice to the address above

Wire transfer: please contact TCI directly

Mail, Fax, or Phone your order to:

Ajay Rastogi
Vice President

Technology Catalysts International Corporation
605 Park Avenue
Falls Church, VA 22046 USA

Telephone: (703) 531-0257

Facsimile: (703) 237-0042

E-mail: arastogi@technology-catalysts.com